A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Clinical trial NCT06612268 · RECRUITING

Trial details

NCT number: NCT06612268
Sponsor: Novo Nordisk A/S
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Sickle Cell Disease

Start date: 2025-02-17
Primary completion: 2027-08-27
Enrollment: 408

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.